Loading data for TARS — first visit, this takes a few seconds.
Tarsus Pharmaceuticals, Inc. (TARS)
NasdaqGS: TARS
· 实时价格 · USD
80.99
-1.78 (-2.15%)
收盘价： Sep 10, 2026, 7:55 PM
股价、关键数字和最新消息，都在这一页。
Tarsus Pharmaceuticals, Inc.（TARS）股价、分析与数据
暂无数据
| 买价 | 59.12 |
| 市值 | 3.56B |
| 营收（TTM） | 606M |
| 净利润（TTM） | -46.5M |
| 0.54 | |
| -1.07 | |
| n/a | |
| 33.55 | |
| 市净率（TTM） | 10.11 |
| 市销率（TTM） | 5.87 |
| 财报日期 | Nov 4, 2026 |
| 卖价 | 104 |
| 成交量 | 281,522 |
| 20日均量 | 1,007,782 |
| 开盘价 | 80.89 |
| 前收盘价 | 82.77 |
| 日内区间 | 80.89 - 83.34 |
| 52周区间 | 48.20 - 91.53 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal h...
公司完整简介财报意外
Tarsus Pharmaceuticals 已于 Aug 6, 2026 发布季度财报：
- 营收为 $173.91M 低于预期 $0, ， 69.41% 同比增长.
- 每股收益为 -0.43 低于预期 -0.23, ， 10.42% 同比增长.
第 1 页，共 2 页